Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

NCT05267054 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG: Ociperlimab
DRUG: Tislelizumab
DRUG: Rituximab

Sponsor

BeiGene